GLAND - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.1
| Stock Code | GLAND | Market Cap | 30,238 Cr. | Current Price | 1,834 ₹ | High / Low | 2,131 ₹ |
| Stock P/E | 25.5 | Book Value | 610 ₹ | Dividend Yield | 0.98 % | ROCE | 15.8 % |
| ROE | 11.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,742 ₹ | DMA 200 | 1,779 ₹ |
| Chg in FII Hold | -0.32 % | Chg in DII Hold | 0.36 % | PAT Qtr | 326 Cr. | PAT Prev Qtr | 302 Cr. |
| RSI | 65.3 | MACD | 19.6 | Volume | 71,773 | Avg Vol 1Wk | 8,20,575 |
| Low price | 1,200 ₹ | High price | 2,131 ₹ | PEG Ratio | -7.43 | Debt to equity | 0.00 |
| 52w Index | 68.1 % | Qtr Profit Var | 10.4 % | EPS | 71.0 ₹ | Industry PE | 29.0 |
📈 Chart & Trend Analysis: GLAND is trading at ₹1,834, above both its 50 DMA (₹1,742) and 200 DMA (₹1,779), indicating short-term bullish strength. RSI at 65.3 suggests the stock is nearing overbought territory, while MACD at 19.6 is positive, confirming upward momentum. Bollinger Bands show price near the upper band, signaling strong momentum but also caution for possible pullbacks.
📊 Volume Trends: Current volume (71k) is significantly lower than the 1-week average (820k), suggesting reduced participation and weakening momentum despite bullish indicators.
🎯 Entry Zone: ₹1,780 – ₹1,820 (support near DMA levels)
🚪 Exit Zone: ₹1,950 – ₹2,000 (resistance near upper trendline and psychological barrier)
🔎 Trend Status: Trending upward in the short term, but showing signs of consolidation due to low volume. Sustained buying pressure is needed for a breakout toward ₹2,000+.
Positive ✅
- Debt-free balance sheet (Debt-to-equity: 0.00).
- EPS of ₹71 supports valuation strength.
- Quarterly PAT growth (₹326 Cr vs ₹302 Cr) shows earnings momentum.
- Strong 52-week performance (68.1% index gain).
Limitation ⚠️
- ROE (11.6%) and ROCE (15.8%) are moderate compared to sector leaders.
- PEG ratio of -7.43 indicates weak growth-adjusted valuation.
- Trading volume is far below average, limiting breakout potential.
Company Negative News 📉
- Decline in FII holdings (-0.32%) suggests reduced foreign investor confidence.
Company Positive News 📈
- Quarterly profit growth of 10.4% shows steady performance.
- DII holdings increased (+0.36%), reflecting domestic institutional support.
Industry 🌐
- Industry P/E at 29.0 indicates sector trades at premium valuations.
- Pharmaceutical sector benefits from global demand and regulatory approvals.
Conclusion 📝
GLAND is trending upward above key moving averages with RSI and MACD supporting bullish momentum. Entry near ₹1,780–₹1,820 offers margin of safety, while exits around ₹1,950–₹2,000 provide profit-taking opportunities. Fundamentally stable with debt-free status and steady earnings growth, but moderate ROE/ROCE and weak volume participation suggest cautious optimism. Traders may play the short-term trend, while long-term investors should accumulate selectively given sector strength.
Would you like me to also prepare a peer benchmarking overlay (comparing GLAND against pharma peers like Divi’s Lab, Biocon, Sun Pharma) so you can evaluate relative strength and sector rotation opportunities?